-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $68

Benzinga·03/10/2025 14:40:38
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $74 to $68.